AUTHOR=Privé Bastiaan M. , Muselaers Constantijn H. J. , van Oort Inge M. , Janssen Marcel J. R. , Peters Steffie M. B. , van Gemert Willemijn A. M. , Uijen Maike J. M. , Schilham Melline M. G. , Sedelaar J. P. Michiel , Westdorp Harm , Mehra Niven , Gotthardt Martin , Barentsz Jelle O. , Gerritsen Winald R. , Witjes J. Alfred , Nagarajah James 

TITLE=An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer

JOURNAL=Frontiers in Nuclear Medicine

VOLUME=Volume 2 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/nuclear-medicine/articles/10.3389/fnume.2022.863101

DOI=10.3389/fnume.2022.863101

ISSN=2673-8880

ABSTRACT=Abstract:
177Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer which could also be applied to patients with hormone sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of 177Lu-PSMA in low volume metastatic hormone sensitive prostate cancer patients. Moreover, we present long-term follow-up data such as toxicity and time without androgen deprivation therapy of the patients that participated in this trial. All in all, 177Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, also at long-term follow-up. We observed that especially men with a prostate-specific antigen (PSA) response of more than 50% seemed to benefit from this therapy by postponing androgen deprivation therapy and thus preserving the quality of life.